

News Release

STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare announces new Future Director appointment

Auckland, New Zealand, 22 June 2018 - Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) announced today that it has selected Claudia Wyss to participate in the Future Directors programme.

Dr Wyss is Chief Executive Officer at Healthvision, a home-based healthcare agency that operates across New Zealand. She has over 25 years' experience in the health industry, with prior roles at McKinsey & Company, as a medical doctor and adviser to governments, hospitals and health systems across New Zealand, the US and UK.

Dr Wyss received her medical degrees at the University of Auckland, and her MBA with a prestigious Dean's Award from Harvard Business School.

The Future Directors programme is an initiative of the Institute of Directors, aimed at giving talented executives exposure to a company board for a 12 to 18 month period in order to develop governance experience. Future directors attend board meetings and observe and participate in discussions, but do not have voting rights. This is the fourth time Fisher & Paykel Healthcare has participated in the programme.

Tony Carter, Chair, said, "We fully support the Future Directors initiative, and are pleased to continue our support this year with Claudia's appointment. We are looking forward to the insights and contribution she will bring, and believe her medical background will be very valuable to the Board."

Dr Wyss said, "I have been a passionate follower of Fisher & Paykel Healthcare for many years. I am thrilled that I can learn more about such an impressive business and its governance practices, apply these lessons to my other roles and contribute wherever possible."

Dr Wyss takes up her role with the company in June 2018 for an 18 month term.

Ends//

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea. The company's products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

Contact:

Investors:

Marcus Driller
General Manager Corporate
marcus.driller@fphcare.co.nz
+64 (0) 27 578 9663

Media:

Rachel Reynolds
Senior Communications Manager
rachel.reynolds@fphcare.co.nz
+64 (0) 21 713 911